# A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

> **NCT01455922** · PHASE3 · WITHDRAWN · sponsor: **Intarcia Therapeutics**

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ITCA 650
- **DRUG:** glimepiride

## Key facts

- **NCT ID:** NCT01455922
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-02
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-12-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01455922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01455922, "A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01455922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*